DESPINA CALAMAR POPOVICI, IOANA IONITA, MIRELA NEDELCU, CLAUDIU IONITA, HORTENSIA IONITA, RADU DUMITRU MOLERIU, CALIN OVIDIU ILIE, DANIELA IACOB, LUCA TUDOR CONSTANTIN, ADELINA CHEVERESAN, DELIA BERCEANU VADUVA, DANIELA RADU COMPLICATIONS OF TYROSINE KINASE INHIBITORS THERAPY IN CHRONIC MYELOID LEUKEMIA - CHRONIC PHASE
Chronic myeloid leukaemia is a malignant tumor of pluripotent haemopoetic stem cell, characterized by increase granulocytes with left shift and the presence of the Ph chromosome.Treatment of chronic phase is made with tyrosine kinase inhibitors administered orally and can have secondary effects: haematological and non-haematological. The purpose of this paper is to assess complications of tyrosine kinase inhibitor therapy in chronic phase of chronic myeloid leukemia and establishing correlations with the type of inhibitor used. The study was performed on a total of 140 patients diagnosed with chronic phase CML in the Hematology Department of the City Clinical Emergency Hospital Timisoara between January 2006 - January 2016. The lot proposed has been studied in terms of anthropometric parameters and also the haematological and biochemical. It showed complications after initiation of therapy with tyrosine kinase inhibitors and also the correlations statistically significant between complications and type of inhibitor used. The study reveals that regardless the type of inhibitor used both haematological complications arise and non haematological. The most common are: neutropenia, thrombocytopenia, anemia, fluid retention, muscle and joint pain. Less common are nausea, diarrhea, abdominal pain, increased liver enzymes. Despite complications of occurring, these modern therapies significantly improve both survival and quality of life of patients.